Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 386,500 shares, a growth of 22.7% from the November 15th total of 315,000 shares. Approximately 5.1% of the shares of the company are sold short. Based on an average daily volume of 3,150,000 shares, the days-to-cover ratio is currently 0.1 days.

Virpax Pharmaceuticals Trading Up 32.9 %

Shares of VRPX stock opened at $0.40 on Friday. Virpax Pharmaceuticals has a 1 year low of $0.29 and a 1 year high of $5.48. The stock has a 50 day simple moving average of $0.56 and a 200 day simple moving average of $0.77.

Analyst Upgrades and Downgrades

Separately, Maxim Group reiterated a “hold” rating on shares of Virpax Pharmaceuticals in a research note on Wednesday, October 9th.

Institutional Trading of Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. 32.23% of the stock is currently owned by institutional investors and hedge funds.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.